全文获取类型
收费全文 | 1081篇 |
免费 | 65篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 51篇 |
妇产科学 | 34篇 |
基础医学 | 108篇 |
口腔科学 | 28篇 |
临床医学 | 73篇 |
内科学 | 289篇 |
皮肤病学 | 9篇 |
神经病学 | 121篇 |
特种医学 | 38篇 |
外科学 | 168篇 |
综合类 | 21篇 |
一般理论 | 2篇 |
预防医学 | 23篇 |
眼科学 | 45篇 |
药学 | 72篇 |
肿瘤学 | 53篇 |
出版年
2024年 | 1篇 |
2023年 | 31篇 |
2022年 | 32篇 |
2021年 | 73篇 |
2020年 | 48篇 |
2019年 | 53篇 |
2018年 | 64篇 |
2017年 | 28篇 |
2016年 | 28篇 |
2015年 | 34篇 |
2014年 | 41篇 |
2013年 | 67篇 |
2012年 | 108篇 |
2011年 | 63篇 |
2010年 | 64篇 |
2009年 | 61篇 |
2008年 | 76篇 |
2007年 | 65篇 |
2006年 | 47篇 |
2005年 | 27篇 |
2004年 | 35篇 |
2003年 | 36篇 |
2002年 | 36篇 |
2001年 | 7篇 |
2000年 | 5篇 |
1999年 | 3篇 |
1998年 | 2篇 |
1997年 | 1篇 |
1995年 | 2篇 |
1994年 | 1篇 |
1992年 | 2篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1988年 | 1篇 |
1983年 | 4篇 |
1982年 | 1篇 |
1972年 | 1篇 |
1949年 | 1篇 |
排序方式: 共有1151条查询结果,搜索用时 15 毫秒
21.
Padrão Eduardo Messias Hirano Bustos Brian Mahesh Ashwin Fonseca Guilherme Henrique Hencklain Taniguchi Leandro Utino 《Annals of hematology》2022,101(9):1951-1957
Annals of Hematology - Sickle cell disease (SCD) is associated with multiple known complications and increased mortality. This study aims to further understand the profile of intensive care unit... 相似文献
22.
William R. Morgenlander Stephanie N. Henson Daniel R. Monaco Athena Chen Kirsten Littlefield Evan M. Bloch Eric Fujimura Ingo Ruczinski Andrew R. Crowley Harini Natarajan Savannah E. Butler Joshua A. Weiner Mamie Z. Li Tania S. Bonny Sarah E. Benner Ashwin Balagopal David Sullivan Shmuel Shoham Thomas C. Quinn Susan H. Eshleman Arturo Casadevall Andrew D. Redd Oliver Laeyendecker Margaret E. Ackerman Andrew Pekosz Stephen J. Elledge Matthew Robinson Aaron A.R. Tobian H. Benjamin Larman 《The Journal of clinical investigation》2021,131(7)
SARS-CoV-2 (CoV2) antibody therapies, including COVID-19 convalescent plasma (CCP), monoclonal antibodies, and hyperimmune globulin, are among the leading treatments for individuals with early COVID-19 infection. The functionality of convalescent plasma varies greatly, but the association of antibody epitope specificities with plasma functionality remains uncharacterized. We assessed antibody functionality and reactivities to peptides across the CoV2 and the 4 endemic human coronavirus (HCoV) genomes in 126 CCP donations. We found strong correlation between plasma functionality and polyclonal antibody targeting of CoV2 spike protein peptides. Antibody reactivity to many HCoV spike peptides also displayed strong correlation with plasma functionality, including pan-coronavirus cross-reactive epitopes located in a conserved region of the fusion peptide. After accounting for antibody cross-reactivity, we identified an association between greater alphacoronavirus NL63 antibody responses and development of highly neutralizing antibodies against CoV2. We also found that plasma preferentially reactive to the CoV2 spike receptor binding domain (RBD), versus the betacoronavirus HKU1 RBD, had higher neutralizing titer. Finally, we developed a 2-peptide serosignature that identifies plasma donations with high anti-spike titer, but that suffer from low neutralizing activity. These results suggest that analysis of coronavirus antibody fine specificities may be useful for selecting desired therapeutics and understanding the complex immune responses elicited by CoV2 infection. 相似文献
23.
Saeheon Jang Sungwon Jung Chiun Pae Blanchard Portland Kimberly J Craig Nelson Ashwin A. Patkar 《Journal of affective disorders》2013
Objective
We investigated patient and disease characteristics predictive of relapse of MDD during a 52-week placebo controlled trial of selegiline transdermal system (STS) to identify patient characteristics relevant for STS treatment.Method
After 10 weeks of open-label stabilization with STS, 322 remitted patients with MDD were randomized to 52-weeks of double-blind treatment with STS (6 mg/24 h) or placebo (PLB). Relapse was defined as Hamilton Depression Rating Scale (HAMD-17) score of ≥14 and a CGI-S score of ≥3 with at least 2-point increase from the beginning of the double blind phase on 2 consecutive visits. Cox's proportional hazards regression was used to examine the effect of potential predictors (age, sex, age at onset of first MDD, early response pattern, number of previous antidepressant trials, severity of index episode, number of previous episodes, melancholic features, atypical features and anxious feature) on outcome. Exploratory analyses examined additional clinical variables (medical history, other psychiatric history, and individual items of HAM-D 28) on relapse.Results
For all predictor variables analyzed, treatment Hazard Ratio (HR=0.48~0.54) was significantly in favor of STS (i.e., lower relapse risk than PLB). Age of onset was significantly predictive of relapse. Type, duration, and severity of depressive episodes, previous antidepressant trials, or demographic variables did not predict relapse. In additional exploratory analysis, eating disorder history and suicidal ideation were significant predictors of relapse after controlling for the effect of treatment in individual predictor analysis.Conclusions
While age of onset, eating disorder history and suicidal ideation were significant predictors, the majority of clinical and demographic variables were not predictive of relapse. Given the post-hoc nature of analysis, the findings need confirmation from a prospective study. It appears that selegiline transdermal system was broadly effective in preventing relapse across different subtypes and symptoms clusters of MDD. 相似文献24.
Alexey A. Shadrin PhD Sören Mucha PhD David Ellinghaus PhD Mary B. Makarious BSc Cornelis Blauwendraat PhD Ashwin A.K. Sreelatha MSc Antonio Heras-Garvin PhD Jinhui Ding PhD Monia Hammer PhD Alexandra Foubert-Samier MD Wassilios G. Meissner MD Olivier Rascol PhD Anne Pavy-Le Traon MD Oleksandr Frei PhD Kevin S. O'Connell PhD Shahram Bahrami PhD Stefan Schreiber MD Wolfgang Lieb MD Martina Müller-Nurasyid PhD Ulf Schminke MD Georg Homuth PhD Carsten O. Schmidt PhD Markus M. Nöthen MD Per Hoffmann PhD Christian Gieger PhD Gregor Wenning MD for the European Multiple System Atrophy Study Group J. Raphael Gibbs PhD Andre Franke PhD John Hardy PhD Nadia Stefanova PhD Thomas Gasser MD Andrew Singleton PhD Henry Houlden MD Sonja W. Scholz MD Ole A. Andreassen PhD Manu Sharma PhD 《Movement disorders》2021,36(2):449-459
25.
26.
Gandham SriLakshmi Bhavani Hitesh Shah Ashwin B. Dalal Anju Shukla Sumita Danda Shagun Aggarwal Shubha R. Phadke Neerja Gupta Madhulika Kabra Kalpana Gowrishankar Anju Gupta Meenakshi Bhat Ratna D. Puri Sunita Bijarnia‐Mahay Sheela Nampoothiri Kavitha M. Mohanasundaram S. Rajeswari Akhil M. Kulkarni Muralidhar L. Kulkarni Prajnya Ranganath A. Radha Ramadevi Sankar V. Hariharan Katta Mohan Girisha 《American journal of medical genetics. Part A》2015,167(10):2481-2484
27.
Huey K Tan Adam Streeter Matthew E Cramp Ashwin D Dhanda 《World journal of hepatology》2020,12(7):389-398
BACKGROUND Zinc is an essential trace element integral to many cellular and immune functions. Zinc deficiency is highly prevalent in patients with cirrhosis and related to disease severity.AIM To evaluate whether zinc supplementation improves clinical outcomes(disease severity and mortality) in patients with cirrhosis.METHODS This prospectively registered systematic review(PROSPERO reference: CRD42018118219) included all studies in Medline, Embase or Cochrane database with inclusion criteria of adult human studies, comparing zinc supplementation of at least 28 d with standard care or placebo in patients with cirrhosis. Mortality and clinical severity score data were extracted. Random effects meta-analyses compared mortality at 6 mo and 2 years. Risk of bias was assessed using the National Institutes of Health quality assessment tool.RESULTS Seven hundred and twelve articles were identified of which four were eligible. Zinc formulations and doses varied(elemental zinc 3.4-214 mg daily) for different intervention periods in patients with differing etiology and severity of cirrhosis. Two studies were considered to be at high risk of bias. There was no significant difference in 6-mo mortality between patients treated with zinc versus controls [risk ratio 0.98(0.90-1.05)]. Changes in severity scores were not reported in any study.CONCLUSION Zinc supplementation is not associated with reduced mortality in patients with cirrhosis. Findings are limited by the small number of eligible studies and significant heterogeneity in intervention and patient population. 相似文献
28.
Alcohol consumption is one of the leading causes of the global burden of disease and results in high healthcare and economic costs. Heavy alcohol misuse leads to alcohol-related liver disease, which is responsible for a significant proportion of alcohol-attributable deaths globally. Other than reducing alcohol consumption, there are currently no effective treatments for alcohol-related liver disease. Oxidative stress refers to an imbalance in the production and elimination of reactive oxygen species and antioxidants. It plays important roles in several aspects of alcohol-related liver disease pathogenesis. Here, we review how chronic alcohol use results in oxidative stress through increased metabolism via the cytochrome P4502E1 system producing reactive oxygen species, acetaldehyde and protein and DNA adducts. These trigger inflammatory signaling pathways within the liver leading to expression of pro-inflammatory mediators causing hepatocyte apoptosis and necrosis. Reactive oxygen species exposure also results in mitochondrial stress within hepatocytes causing structural and functional dysregulation of mitochondria and upregulating apoptotic signaling. There is also evidence that oxidative stress as well as the direct effect of alcohol influences epigenetic regulation. Increased global histone methylation and acetylation and specific histone acetylation inhibits antioxidant responses and promotes expression of key pro-inflammatory genes. This review highlights aspects of the role of oxidative stress in disease pathogenesis that warrant further study including mitochondrial stress and epigenetic regulation. Improved understanding of these processes may identify novel targets for therapy. 相似文献
29.
Proeschold-Bell RJ Patkar AA Naggie S Coward L Mannelli P Yao J Bixby P Muir AJ 《Digestive diseases and sciences》2012,57(4):1083-1091
Background
Patients with chronic hepatitis C virus (HCV) infection have high rates of alcohol consumption, which is associated with progression of fibrosis and lower response rates to HCV treatment. 相似文献30.